AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone that Metabolic Pharmaceuticals developed in the late 1990s and early 2000s as an anti-obesity candidate. The honest bottom line is that preclinical and animal work showed fat-reducing activity, but a Phase 2b human obesity trial failed to beat placebo, development was halted, and the compound has never been approved as a drug or accepted as a legal US dietary supplement ingredient. It circulates today as a gray-market "research chemical," so its popular reputation as a fat-loss peptide runs well ahead of its actual evidence and legal standing.
AOD-9604 is a growth-hormone fragment whose obesity development was discontinued after a Phase 2b trial showed no weight loss beyond placebo, and it holds no drug approval or legal US dietary-supplement status.
AOD-9604 is the last sixteen amino acids of human growth hormone, the 176-to-191 stretch at the hormone's C-terminus, with a single tyrosine added to the front for stability. Earlier research had flagged that C-terminal region as the part of growth hormone carrying its fat-metabolizing signal, which is why Metabolic Pharmaceuticals singled it out and built the fragment synthetically rather than using the whole hormone.
AOD-9604 is a synthetic peptide corresponding to amino acids 176 to 191 of human growth hormone with an added tyrosine, created by Metabolic Pharmaceuticals to isolate the hormone's fat-metabolizing C-terminal region.
The proposed mechanism centers on lipolysis, the breakdown of stored triglycerides in fat cells into free fatty acids that can be burned for energy. AOD-9604 is described as reproducing the lipolytic signal that growth hormone's C-terminal region sends to fat tissue while discouraging the laying-down of new fat. The evidence for this pathway comes mostly from cell cultures and animal models, so its strength in living, dosed humans is far less settled than marketing summaries suggest.
AOD-9604's proposed fat-loss action is lipolysis driven through the beta-3 adrenergic pathway, but the supporting evidence is largely from cell and animal models rather than robust human data.
The clearest signal from the clinical record is that AOD-9604 did not deliver on its central promise. Rodent obesity models showed reduced body weight and fat mass, and early human studies found it reasonably tolerated, but the pivotal placebo-controlled Phase 2b trial in obese adults produced no weight loss meaningfully greater than placebo. Metabolic Pharmaceuticals discontinued the obesity program on that result, the single most important and most often omitted fact about its effectiveness.
AOD-9604's pivotal placebo-controlled Phase 2b obesity trial failed to produce weight loss beyond placebo, and Metabolic Pharmaceuticals discontinued its development as an obesity drug on that outcome.
AOD-9604 is not an approved drug anywhere, and it does not hold a legitimate place as a US dietary supplement. No major regulator has cleared it for obesity or any other condition, an attempt to treat it as a permissible dietary ingredient was not accepted, and the "research use only" labeling on gray-market supply is a seller's disclaimer rather than any grant of legal human use.
AOD-9604 is not an FDA-approved drug, was rejected as a legal US dietary ingredient, was not endorsed for pharmacy compounding, and is prohibited in sport under World Anti-Doping Agency rules.
Inside its clinical trials, AOD-9604 was generally described as well tolerated, with mild side effects not clearly different from placebo, but "well tolerated in short trials" is a far weaker statement than "safe." The pressing hazards come from how the substance is actually supplied and used today: gray-market product with no oversight on purity, dose, sterility, or even identity, and no long-term human safety data at all.
| Concern | In clinical trials | In gray-market use |
|---|---|---|
| Tolerability | Mild effects, not clearly above placebo | Short-term signals only, no long-term data |
| Product quality | Controlled manufacture and dose | Purity, dose, sterility, identity not guaranteed |
| Oversight | Medical supervision and monitoring | None; unregulated supply chain |
| Injection hazards | Managed sterile handling | Infection and injection-site reactions |
AOD-9604 showed only mild short-term tolerability in its discontinued trials, while gray-market supply carries unquantified risks from unverified purity, dose, sterility, and identity, with no long-term human safety data.
In formal research, AOD-9604 was studied mainly as a subcutaneous injection, though the developers also invested in an oral formulation, since a capsule fat-loss agent was central to the commercial appeal, and transdermal delivery was explored in some contexts. The decisive point is that none of this amounts to an approved dosing protocol: with development halted, there is no regulator-sanctioned label, no validated dose, and no official guidance on frequency, duration, or safe limits.
AOD-9604 was studied by subcutaneous injection and in oral and transdermal formulations, but because development was halted it has no approved label, validated dose, or official guidance on frequency, duration, or safe limits.
After the obesity program stalled, AOD-9604's most notable second life was in joint and cartilage health, where it was investigated, including in combination with other agents, for cartilage regeneration and osteoarthritis. This kind of repurposing is common when a compound clears early safety hurdles but fails its lead indication, yet none of these avenues produced an approved product or a robust body of evidence.
Beyond obesity, AOD-9604 was investigated mainly for cartilage regeneration and osteoarthritis, but these applications remained exploratory and none reached an approved product or a robust body of evidence.
The most important comparison is with today's approved weight-loss medicines, above all the GLP-1 receptor agonists such as semaglutide, and on evidence it is not a close contest. Those drugs carry large placebo-controlled trials showing substantial, sustained weight loss, formal approval, and defined dosing, while AOD-9604 has a discontinued program that failed to beat placebo and no approval at all.
| Criterion | AOD-9604 | GLP-1 agonists (e.g., semaglutide) |
|---|---|---|
| Human efficacy | Failed to beat placebo in Phase 2b | Substantial, sustained loss in large trials |
| Regulatory status | No approval; development halted | FDA-approved for chronic weight management |
| Dosing | No validated protocol | Defined, monitored dosing |
| Access | Cheap, gray-market, no prescription | Prescription, clinician-monitored |
On demonstrated human efficacy, approval, and defined dosing, AOD-9604 sits well behind approved GLP-1 receptor agonists such as semaglutide, which have large trials showing substantial, sustained weight loss.
A realistic appraisal starts with the evidence gap: the peptide's own lead clinical program failed to show meaningful weight loss, so the expectation of a strong fat-loss effect is not well founded. Because AOD-9604 sits outside the approved-medicine system, the guidance and quality controls built into regulated care are absent, and a sober risk-versus-benefit reading tends to favor caution.
A sober risk-versus-benefit reading of AOD-9604 favors caution, because its lead clinical program failed, its gray-market quality is unverified, and regulated weight-management options with real human evidence now exist.
Educational use only. This article describes what the published scientific and clinical literature reports about AOD-9604. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
